Clinical Trial Update: A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and pharmacodynamic study to characterize blood levels of canagliflozin (JNJ-28431754) in adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED